This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
MSL2 ensures biallelic gene expression in mammals
Nature Open Access 29 November 2023
-
Contextual fear memory impairment in Angelman syndrome model mice is associated with altered transcriptional responses
Scientific Reports Open Access 30 October 2023
-
Novel epigenetic molecular therapies for imprinting disorders
Molecular Psychiatry Open Access 25 August 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hochstrasser, M. Ann. Rev. Genet. 30, 405–439 (1996).
Kishino, T., Laland, M. & Wagstaff, J., Nature Genet. 15, 70–73 (1997).
Matsuura, T. et al. Nature Genet. 15, 74–77 (1997).
Knoll, J.H.M. et al. Am. J. Med. Genet. 32, 285–290 (1989).
Wagstaff, J. et al. Nature Genet. 1, 291–294 (1992).
Nakao, M. et al. Hum. Mol. Genet. 3, 309–315 (1994).
Huibregtse, J.M., Scheffner, M. & Howley, P.M. Mol. Cell. Biol. 13, 775–784 (1993).
Vu, T.H. & Hoffman, A.R. Nature 371, 714–717 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vu, T., Hoffman, A. Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. Nat Genet 17, 12–13 (1997). https://doi.org/10.1038/ng0997-12
Issue Date:
DOI: https://doi.org/10.1038/ng0997-12
This article is cited by
-
A heterozygous mutation in UBE2H in a patient with developmental delay leads to an aberrant brain development in zebrafish
Human Genomics (2023)
-
MSL2 ensures biallelic gene expression in mammals
Nature (2023)
-
Contextual fear memory impairment in Angelman syndrome model mice is associated with altered transcriptional responses
Scientific Reports (2023)
-
Novel epigenetic molecular therapies for imprinting disorders
Molecular Psychiatry (2023)
-
Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments
Neurotherapeutics (2021)